Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;109(9):800-803.
doi: 10.1093/bjs/znac131.

Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study

Collaborators, Affiliations

Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study

Hiba Fatayer et al. Br J Surg. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Surgical management, showing surgical plan at diagnosis and actual surgical management after systemic therapy MDT, multidisciplinary team; NACT, neoadjuvant chemotherapy; IBR, immediate breast reconstruction; BCS, breast-conserving surgery.

References

    1. Makris A, Powles T, Ashley S, Chang J, Hickish T, Tidy V et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179. - PubMed
    1. Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg 2000;190:350–363 - PubMed
    1. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455–1461 - PMC - PubMed
    1. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 2017;35:1049. - PMC - PubMed
    1. Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19:497–509 - PubMed